ALFA Finder| Metric | Q4 FY26 | Q4 FY25 | |
|---|---|---|---|
| Revenue from operations | 103.7 | — | 101.0 |
| Total income | 103.7 | — | 101.0 |
| Profit before exceptional items & tax | 17.3 | — | 17.9 |
| Profit before tax | 17.3 | — | 17.9 |
| Net profit | 13.1 | — | 13.4 |
| Operating margin | 16.7% | — | 17.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -2.20% |
|---|---|
| Revenue, year on year | +2.70% |
NSE results filing, NSE: PAR. Figures extracted from the filing.
Par Drugs & Chemicals Ltd: key numbers
- Share price
- ₹118.11
- Market cap
- ₹145.3 Cr
- Revenue (annual)
- ₹103.7 Cr
- Net profit (annual)
- ₹13.11 Cr
- P/E (TTM)
- 11.2×Sector 43.8×
- Promoter holding
- 73.41%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Par Drugs & Chemicals Ltd
All →Par Drugs & Chemicals Q2 FY27 Results: Net Profit ₹2.6 Cr, Down 36.6% YoY
Par Drugs & Chemicals Ltd reported revenue from operations of ₹27.4 Cr (-4.5% YoY) and net profit of ₹2.6 Cr (-36.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹2.6 Cr · -36.6% YoY
Par Drugs & Chemicals Board Meeting Date
Par Drugs and Chemicals Limited will hold a board meeting on October 29, 2026, to consider and approve its half-yearly unaudited financial results.
Par Drugs & Chemicals Other Announcement
The company submitted the routine Regulation 74(5) compliance certificate from its RTA regarding share dematerialization for the quarter ended September 30, 2026.
Par Drugs & Chemicals Management Change
Par Drugs re-appointed its statutory auditor and executive director/CEO. These appointments were approved at the company's 27th Annual General Meeting.
Par Drugs & Chemicals Annual General Meeting
Par Drugs and Chemicals Limited held its 27th Annual General Meeting on September 26, 2026. Management reviewed the company's financial performance and business affairs during the session.
Par Drugs & Chemicals Other Announcement
Par Drugs and Chemicals Limited is notifying shareholders about access to the FY 2025-26 Annual Report and 27th AGM notice via web-link.